BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
311.65
-1.89 (-0.60%)
Oct 23, 2025, 11:41 AM EDT - Market open
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.32B in the quarter ending June 30, 2025, with 41.56% growth. This brings the company's revenue in the last twelve months to $4.56B, up 47.33% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.56B
Revenue Growth
+47.33%
P/S Ratio
7.34
Revenue / Employee
$414,727
Employees
11,000
Market Cap
34.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ONC News
- 1 day ago - BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6 - Business Wire
- 3 days ago - BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 - Business Wire
- 8 days ago - BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline - Seeking Alpha
- 10 days ago - BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA - Business Wire
- 6 weeks ago - BeOne Medicines AG (ONC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 7 weeks ago - BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients - Benzinga
- 7 weeks ago - BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL) - Business Wire
- 2 months ago - European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025 - Business Wire